Patents Assigned to Chiesi Farmaceutici S.p.A.
  • Publication number: 20250100997
    Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-? (TGF-?) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
    Type: Application
    Filed: January 10, 2023
    Publication date: March 27, 2025
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Daniela PIZZIRANI, Paolo RONCHI, Donatella RESCIGNO
  • Publication number: 20250066341
    Abstract: The present invention relates to a compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are cyclohexane acid derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.
    Type: Application
    Filed: December 21, 2022
    Publication date: February 27, 2025
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Elisabetta ARMANI, Gabriele AMARI, Mafalda PAGANO, Marta GIULIANI
  • Publication number: 20250059195
    Abstract: The present invention generally relates to a novel triazolone derivative salt particularly useful as neutrophil elastase inhibitor and to its use as medicament; the invention also relates to its synthesis process and pharmaceutical compositions thereof. The invention also relates to the process for the isolation by crystallization of the compound (I). The invention also relates to a crystal form of a compound of formula (I).
    Type: Application
    Filed: December 21, 2022
    Publication date: February 20, 2025
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Irene BASSANETTI, Francesco AMADEI
  • Publication number: 20250057825
    Abstract: Pharmaceutical formulations comprising clevidipine in an oil-in-water formulation that is resistant to microbial growth and stable against the formation of impurities.
    Type: Application
    Filed: April 10, 2024
    Publication date: February 20, 2025
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Rajeshwar MOTHERAM, Gregory Charles WILLIAMS
  • Publication number: 20250051340
    Abstract: The present invention generally relates to a novel triazolone derivative salt particularly useful as neutrophil elastase inhibitor and to its use as a medicament. The present invention also relates to pharmaceutical compositions comprising the novel triazolone derivative salt and one or more pharmaceutically acceptable carriers and/or excipients thereof and to their use as medicament.
    Type: Application
    Filed: December 21, 2022
    Publication date: February 13, 2025
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Gabriele AMARI, Carmelida CAPALDI, Elisabetta ARMANI
  • Patent number: 12214129
    Abstract: A laryngeal mask airway device includes an airway tube and a laryngeal mask placed at a distal end of the airway tube. The distal end of the airway tube opens inside the laryngeal mask. The device includes a connector placed at a proximal end of the airway tube. The connector is in fluid communication with the laryngeal mask through the airway tube and is configured to be connected to a ventilation equipment. The device includes a movable element placed in the laryngeal mask and configured to steer a tip of a catheter passing through the airway tube. The device further includes a control element mounted on the proximal end of the airway tube and a motion transmission device operatively connected to the movable element and to the control element to move the movable element and to steer the tip of the catheter by acting on the control element.
    Type: Grant
    Filed: November 29, 2019
    Date of Patent: February 4, 2025
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: John Kenneth Hainsworth, George Robert Butcher, Peter Ryan Smith, Thomas Henry Shaw, Anthony Robinson
  • Publication number: 20250011299
    Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-? (TGF-?) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
    Type: Application
    Filed: September 20, 2022
    Publication date: January 9, 2025
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Daniela PIZZIRANI, Paolo RONCHI, Sara GUARIENTO, Daniele PALA, Paolo BRUNO, Teresa SEMERARO, Donatella RESCIGNO
  • Publication number: 20240425482
    Abstract: The present invention relates to compounds of formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, intermediate compounds useful in such preparations, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.
    Type: Application
    Filed: October 17, 2022
    Publication date: December 26, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Laura CARZANIGA, Fabio RANCATI, Andrea RIZZI, Eleonora GHIDINI, Nicolò IOTTI, Roberta MAZZUCATO, Stefano LEVANTO, Ben Paul WHITTAKER
  • Publication number: 20240391936
    Abstract: The present invention relates to compounds of general formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.
    Type: Application
    Filed: March 25, 2022
    Publication date: November 28, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Laura CARZANIGA, Andrea RIZZI, Nicoió IOTTI, Fabio RANCATI, Anna KARAWAJCZYK, Barbara Karolina WOLEK, David Edward CLARK, Toby Matthew Grover MULLINS, Keith Christopher KNIGHT, Ben Paul WHITTAKER, Stefano LEVANTO
  • Publication number: 20240366682
    Abstract: This invention is directed to a process for the preparation of an exogenous pulmonary surfactant, in particular a modified natural surfactant or a reconstituted surfactant, wherein the final filtration step is performed without the use of chlorinated solvents. The invention is also directed to the product as obtained by said process, and to the corresponding pharmaceutical compositions.
    Type: Application
    Filed: July 4, 2022
    Publication date: November 7, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Tomaso GUIDI, Luca RIZZO, Monica BOCCHI
  • Publication number: 20240350638
    Abstract: The present invention is directed to the following: methods of treating or preventing stent thrombosis using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; methods of reducing mortality in a subject undergoing stent implantation using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; medicaments comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation; pharmaceutical compositions comprising cangrelor and bivalirudin; and methods of preparing a medicament comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation.
    Type: Application
    Filed: March 5, 2024
    Publication date: October 24, 2024
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Clive Arthur Arculus-Meanwell, Simona Skerjanec
  • Publication number: 20240342205
    Abstract: The present invention is directed to the use of cangrelor for the treatment and/or prevention of shunt thrombosis in patients suffering congenital heart diseases undergoing shunt surgery. The invention is also directed to the use of cangrelor for the treatment and/or prevention of stent thrombosis in pediatric patients undergoing stent implantation.
    Type: Application
    Filed: February 21, 2024
    Publication date: October 17, 2024
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventor: Thomas Diacovo
  • Patent number: 12097329
    Abstract: An apparatus to administer drugs to mechanically ventilated patients includes a mechanical ventilator, an artificial airway to be associated to a patient and a ventilation circuit connecting the mechanical ventilator to the artificial airway. The ventilation circuit includes: an inspiratory line, a dry powder inhaler disposed in line on the inspiratory line and a connector operatively connected to the dry powder inhaler and to the inspiratory line. The connector includes: a first duct facing an outlet port of the dry powder inhaler and connected or configured to be connected to a tube section of the inspiratory line placed downstream the dry powder inhaler; a second duct facing an air inlet port of the dry powder inhaler and connected or configured to be connected to a tube section of the inspiratory line placed upstream the dry powder inhaler.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: September 24, 2024
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Ruben Agazzi, Benedetta Campolo, Nicolò Dallacasa, Edoardo Davico, Chantal Erika Speziali
  • Publication number: 20240279240
    Abstract: The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of the JAK family non-receptor kinases; in particular for the treatment of various inflammatory disease including asthma, COPD and other respiratory diseases.
    Type: Application
    Filed: March 14, 2022
    Publication date: August 22, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Alessandro ACCETTA, Fabio RANCATI, Andrea RIZZI, Alberto CUZZOLIN, Milan MESIC, Rahela ZADRAVEC, Dinko ZIHER, Ivaylo ELENKOV
  • Publication number: 20240217967
    Abstract: The present invention relates to compounds of general formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.
    Type: Application
    Filed: March 25, 2022
    Publication date: July 4, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Laura CARZANIGA, Fabio RANCATI, Andrea RIZZI, Nicolò IOTTI, Keith Christopher KNIGHT, Toby Matthew Grover MULLINS, Anna KARAWAJCZYK, Ben Paul WHITTAKER
  • Publication number: 20240209001
    Abstract: The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of the JAK family non-receptor kinases; in particular for the treatment of various inflammatory disease including asthma, COPD and other respiratory diseases.
    Type: Application
    Filed: March 14, 2022
    Publication date: June 27, 2024
    Applicant: CHIESI FARMACEUTICI S.P. A.
    Inventors: Alessandro ACCETTA, Fabio RANCATI, Andrea RIZZI, Alberto CUZZOLIN, Milan MESIC, Dinko ZIHER, Ivaylo ELENKOV, Kristina BUTKOVIC
  • Patent number: 12016850
    Abstract: The disclosure is directed to pharmaceutical compositions for oral administration comprising deferiprone. In particular, the disclosure is also directed to modified release tablets suitable either for twice daily administration or once daily administration. The disclosure is also directed to methods of making and using the same.
    Type: Grant
    Filed: April 11, 2022
    Date of Patent: June 25, 2024
    Assignees: Chiesi Farmaceutici S.p.A., Università degli Studi di Milano
    Inventors: Marisa Pertile, Andrea Gazzaniga, Matteo Cerea, Micol Cirilli
  • Patent number: 12016851
    Abstract: The disclosure is directed to pharmaceutical compositions for oral administration in form of coated tablets that exhibit modified release properties when administered as either whole or half tablets. In particular, the disclosure is directed to modified release tablets comprising deferiprone, said tablets being suitable for twice daily oral administration. The disclosure is also directed to methods of making and using the same.
    Type: Grant
    Filed: April 11, 2022
    Date of Patent: June 25, 2024
    Assignees: Chiesi Farmaceutici S.p.A., Università degli Studi di Milano
    Inventors: Marisa Pertile, Andrea Gazzaniga, Matteo Cerea, Micol Cirilli
  • Publication number: 20240199635
    Abstract: The present invention relates to compounds of general formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.
    Type: Application
    Filed: March 25, 2022
    Publication date: June 20, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Laura CARZANIGA, Fabio RANCATI, Andrea RIZZi, Keith Christopher KNIGHT, Anna KARAWAJCZYK, Barbara Karolina WOLEK, Toby Matthew Grover MULLINS, Ben Paul WHITTAKER
  • Publication number: 20240190847
    Abstract: The present invention relates to compounds of general formula (I) inhibiting DDR1 and DDR2. Particularly, the invention relates to compounds that are indoline derivatives, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of DDRs, in particular fibrosis.
    Type: Application
    Filed: March 25, 2022
    Publication date: June 13, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Laura CARZANIGA, Fabio RANCATI, Andrea RIZZI, Anna KARAWAJCZYK, Barbara Karolina WOLEK, Toby Matthew Grover MULLINS